Holen Sie sich die Stockscreener-App
13.39
9.95%
-1.48
Handel nachbörslich:
13.65
0.26
+1.94%
Erasca Inc Aktie (ERAS) Neueste Nachrichten
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - GlobeNewswire Inc.
Erasca, Inc. (NASDAQ: ERAS) foundation plans another ERAS stock sale - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Erasca, Inc. (ERAS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Investors to Connect - ACCESS Newswire
Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2026. - marketscreener.com
Attention Long-Term Shareholders of Aardvark Therapeutics, - GlobeNewswire
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium - manilatimes.net
Important Notice to Long-Term Shareholders of Erasca, Inc. - GlobeNewswire
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Erasca stock holds gains as FDA Fast Track boosts cancer pipeline - ad-hoc-news.de
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage - Yahoo Finance
Erasca stock gains visibility as FDA fast tracks ERAS-0015 - ad-hoc-news.de
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: - GlobeNewswire
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims - GlobeNewswire
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Should FDA Fast Track for ERAS-0015’s Pan-RAS Glue Require Action From Erasca (ERAS) Investors? - simplywall.st
Important Notice to Long-Term Shareholders of Erasca, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Stockholders to Connect - ACCESS Newswire
Erasca receives FDA fast track status for pancreatic cancer drug - investing.com
INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit - Eastern Progress
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities LawsuitContact The Gross Law Firm - Eastern Progress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc.ERAS - Eastern Progress
Erasca (ERAS) Momentum: Slides 5.67% to $17.05 in the Latest Session; Immediate View: Traders Can Monitor the $16.20-$17.90 Range for the Current SessionIchimoku Kumo Twist - Vinanet
E Fund Management Co. Ltd. Invests $4.86 Million in Erasca, Inc. $ERAS - MarketBeat
Law firm probes Erasca directors for possible b... - Pluang
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB - MarketBeat
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com Nigeria
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - Sahm
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Erasca stock, $30 target - Investing.com
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com India
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com UK
Stifel reiterates Buy rating on Erasca stock, $30 target - Investing.com
Erasca (NASDAQ: ERAS) foundation to sell 8,333 shares - Stock Titan
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - simplywall.st
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - simplywall.st
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - webull.com
ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes - Stock Titan
ERAS Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
Bank of America Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price - MarketBeat
Erasca, Inc. Stock 12‑Month Price Target Raised to $23, Implies 29% Upside - TradingView
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
6.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):